study 329造句

• Medical ethicists Linsey Goey and Emily Jackson write that the 1998 SmithKline Beecham position paper, in which the company said it had decided not to show studies 329 and 377 to regulators,
• Funded by SmithKline Beecham, study 329 was an eight-week, double-blind, randomized clinical trial conducted in 12 university or hospital psychiatric departments in the United States and Canada between 1994 and 1997.
• The controversy led to several lawsuits and strengthened calls for drug companies to disclose all their clinical research data . " New Scientist " wrote in 2015 : " You may never have heard of it, but Study 329 changed medicine ."
• In October 1998 the neurosciences division of SmithKline Beecham's Central Medical Affairs ( CMAT ) department distributed a position paper, " Seroxat / Paxil Adolescent Depression : Position piece on the phase III clinical studies . " The paper discussed studies 329 and 377.
• It stated that study 329 had shown " trends in efficacy in favour of Seroxat / Paxil across all indices of depression . . . [ but had ] failed to demonstrate a statistically significant difference from placebo on the primary efficacy measures . " Study 377 had shown a high placebo response rate and had " failed [ to ] demonstrate any separation of Seroxat / Paxil from placebo . " The company decided to publish study 329 but not 377, and not to submit either trial to the regulators, because they were " insufficiently robust to support a label change " for adolescent use ."
• It stated that study 329 had shown " trends in efficacy in favour of Seroxat / Paxil across all indices of depression . . . [ but had ] failed to demonstrate a statistically significant difference from placebo on the primary efficacy measures . " Study 377 had shown a high placebo response rate and had " failed [ to ] demonstrate any separation of Seroxat / Paxil from placebo . " The company decided to publish study 329 but not 377, and not to submit either trial to the regulators, because they were " insufficiently robust to support a label change " for adolescent use ."